Introduction {#tca12757-sec-0001}
============

EGFR is a cell surface protein with cytoplasmic kinase activity that transduces important growth factor signals from extracellular regions. EGFR is overexpressed in \> 60% of non‐small cell lung cancers (NSCLCs) and plays a crucial role in regulating cell proliferation, survival, motility, and differentiation.[1](#tca12757-bib-0001){ref-type="ref"} In addition, *EGFR* mutations, including mutations in the tyrosine kinase domain (exons 18--21), and increased gene copy numbers, are frequently detected in NSCLC patients.[2](#tca12757-bib-0002){ref-type="ref"} Furthermore, specific types of activating mutations are associated with enhanced sensitivity to EGFR‐tyrosine kinase inhibitors (TKIs).[3](#tca12757-bib-0003){ref-type="ref"}

Several studies have investigated the associations between *EGFR* polymorphisms and lung cancer.[4](#tca12757-bib-0004){ref-type="ref"}, [5](#tca12757-bib-0005){ref-type="ref"} However, previous studies have been performed to identify functional polymorphisms that are located in the coding, promoter, and untranslated regions of *EGFR*.[6](#tca12757-bib-0006){ref-type="ref"} Although a few studies have investigated polymorphisms in the *EGFR* intron or non‐coding regions, these studies mainly focused on single nucleotide polymorphisms (SNPs) in the intron 1 region, which have been shown to potentially influence promoter activity.[7](#tca12757-bib-0007){ref-type="ref"}

Genome‐wide association studies (GWAS) have reported that most of the currently identified disease and trait‐associated SNPs are intronic or intergenic.[8](#tca12757-bib-0008){ref-type="ref"} Post‐GWAS efforts are now focused on performing functional characterization of these associations. Some newly discovered GWAS variants have been annotated as cell‐type‐specific gene enhancer elements by integrating knowledge of regulatory sequences (e.g. histone modification and DNase sensitivity).[9](#tca12757-bib-0009){ref-type="ref"}, [10](#tca12757-bib-0010){ref-type="ref"}, [11](#tca12757-bib-0011){ref-type="ref"} Pomerantz *et al*. reported that the 8q24 colorectal cancer risk variant, rs6983267, participates in long‐range physical interactions with the MYC proto‐oncogene.[11](#tca12757-bib-0011){ref-type="ref"}

Data from the Encyclopedia of DNA elements (ENCODE) and the Roadmap Epigenome Project can provide better interpretation of the non‐coding sequences of the genome.[12](#tca12757-bib-0012){ref-type="ref"} As a result, the RegulomeDB database, which integrates data from ENCODE and other major databases, was developed to enable regulatory and epigenomic annotation of any set of variants derived from GWAS or genomic sequencing.[13](#tca12757-bib-0013){ref-type="ref"} These systematically annotated data have recently been used to elucidate the mechanisms by which GWAS variants that are located in non‐coding regions can influence clinically relevant phenotypes. These studies have identified the potential variants that demonstrate regulatory functions and have provided insights on the mechanisms that underlie the functions of these variants. To further verify the impact of regulatory SNPs in the *EGFR* gene on lung cancer prognosis, we evaluated the association of the potentially functional SNPs predicted by RegulomeDB and the survival outcomes of surgically resected NSCLC patients.

Methods {#tca12757-sec-0002}
=======

Patient characteristics {#tca12757-sec-0003}
-----------------------

This study included NSCLC patients who underwent curative surgical resection at the Kyungpook National University Hospital between September 1998 and December 2007 (*n* = 316) and at the Seoul National University Bundang Hospital between September 2005 and March 2012 (*n* = 382). The clinicopathologic characteristics of the patients and associations with overall survival (OS) and disease‐free survival (DFS) are shown in Table [S1](#tca12757-supitem-0001){ref-type="supplementary-material"}. All patients were of Korean ethnicity. The institutional review boards of the two hospitals approved this study.

Single nucleotide polymorphism (SNP) selection and genotyping {#tca12757-sec-0004}
-------------------------------------------------------------

RegulomeDB is a database that functionally annotates the regulatory features of SNPs in the human genome based on experimental datasets derived from ENCODE and other sources, as well as computational predictions and manual annotations.[13](#tca12757-bib-0013){ref-type="ref"} RegulomeDB employs a six‐category system to interpret functional variants. Categories 1--3 comprise SNPs with strong evidence of binding based on ChIP‐seq and DNase footprints. However, categories 4--6 still lack experimental evidence to demonstrate that the variant actually disrupts the binding site. We obtained a total of 942 SNPs within the *EGFR* gene region, NC_000007.13 (55086678.0.55279262, complement) by Genome Reference Consortium Human Build 37 patch release 13 (GRCh37.p13) assembly, using RegulomeDB (<http://regulome.stanford.edu>). We prioritized 124 SNPs that were classified under categories 1--3 because a lower score suggests stronger evidence of binding and indicates that a variant is located in a functional region. Among the 124 polymorphisms, seven SNPs (rs9642391C\>G, rs1554718T\>C, rs7792797A\>C, rs11534100C\>T, rs12718945G\>T, rs11977660C\>T, and rs2302535C\>A) were selected after excluding 111 polymorphisms with minor allele frequency \< 0.1 in HapMap JPT and six SNPs in strong linkage disequilibrium (*r* ^2^ \> 0.8). All SNPs were genotyped using MassARRAY iPLEX assay (Sequenom Inc., San Diego, CA, USA) according to the manufacturer\'s instructions. For genotype validation, approximately 5% of the cohort samples were randomly selected for repeated genotyping via a restriction fragment length polymorphism assay by a different investigator; the results were 100% concordant.

Quantitative reverse transcription‐PCR {#tca12757-sec-0005}
--------------------------------------

Quantitative reverse transcription (qRT)‐PCR was performed to determine the expression of human *EGFR* and *GBAS*. Trizol reagent (Invitrogen, Carlsbad, CA, USA) was used to extract total RNA from fresh tumors and paired non‐malignant lung tissues of 144 NSCLC patients who underwent surgery at Kyungpook National University Medical Center. Real‐time PCR was performed in triplicate using QuantiFast SYBR Green PCR Master Mix (Qiagen, Hilden, Germany) in a LightCycler 480 (Roche Applied Science, Mannheim, Germany). For each target transcript, PCR was performed with a final reaction volume of 10 μL containing 1 μL of complimentary DNA, 5 μL of mix, and 1 μL of each primer. All complementary DNA samples were prepared in a 1:5 dilution to obtain results within the range of the standard. Relative messenger RNA (mRNA) expression levels were normalized against β‐actin expression and calculated via the 2^−ΔΔCt^ method.

Statistical analysis {#tca12757-sec-0006}
--------------------

Hardy--Weinberg equilibrium was tested by comparing the observed and expected genotype frequencies using a goodness‐of‐fit χ^2^ test. The Kaplan--Meier method and log‐rank test were used to estimate OS and DFS. Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated for multivariate statistical models, with adjustments for age, gender, smoking status, pathologic stage, and adjuvant therapy. A paired *t*‐test was used to compare *EGFR* and *GBAS* mRNA expression between tumor and normal tissues. All analyses were performed using SAS version 9.2 (SAS Institute Inc., Cary, NC, USA).

Results {#tca12757-sec-0007}
=======

The clinical characteristics of the 698 patients enrolled in this study are shown in Table [S1](#tca12757-supitem-0001){ref-type="supplementary-material"}. There were 209 deaths (29.9%), and the estimated five‐year OS and DFS rates for all patients were 60% (95% CI 55--65%) and 43% (95% CI 38--47%), respectively. Pathological stage was found to be significantly associated with OS and DFS (both log‐rank *P* \[*P* ~L‐R~\] \< 0.0001). Gender and smoking status were also associated with OS (*P* ~L‐R~ \< 0.0001) and DFS (*P* ~L‐R~ = 0.03).

Statistical analysis of SNPs showed that all genotype frequencies were in Hardy--Weinberg equilibrium. Among the seven SNPs examined, only rs9642391 (*EGFR* ivs19+2851C\>G) was significantly associated with OS and DFS (Table [1](#tca12757-tbl-0001){ref-type="table"}). The rs9642391 C\>G variant was found to be significantly associated with increased survival (adjusted HR \[aHR\] for OS = 0.70, 95% CI 0.56--0.87, *P* = 0.001; aHR for DFS = 0.82, 95% CI 0.70--0.97, *P* = 0.02; under a codominant model) (Table [2](#tca12757-tbl-0002){ref-type="table"}, Fig [1](#tca12757-fig-0001){ref-type="fig"}).

###### 

Seven SNPs of log‐rank *P* in overall and disease‐free survival

                                                         Overall survival   Disease‐free survival                        
  ------------ ------------ ---- ---- ---- ------ ------ ------------------ ----------------------- ------ ------ ------ ------
  rs9642391    ivs19+2851   1d   CG   99   0.36   0.78   0.01               0.01                    0.03   0.05   0.06   0.03
  rs11534100   ivs2−12589   2b   CT   97   0.29   0.39   0.61               0.32                    0.90   0.41   0.26   0.72
  rs12718945   ivs2−17016   3a   GT   96   0.30   0.94   0.78               0.80                    0.59   0.38   0.18   0.96
  rs11977660   ivs2−47673   2a   CT   98   0.33   0.77   0.09               0.03                    0.22   0.49   0.23   0.69
  rs2302535    ivs2−55291   2b   CA   99   0.12   0.53   0.21               0.10                    0.27   0.59   0.40   0.76
  rs1554718    ivs21−3449   2b   TC   98   0.14   0.55   0.63               0.84                    0.34   0.43   0.23   0.40
  rs7792797    \*5601       2b   AC   98   0.34   0.70   0.61               0.96                    0.34   0.42   0.50   0.20

Information about single nucleotide polymorphisms (SNPs) and SNP ID were obtained from the National Center for Biotechnology Information database (<http://ncbi.nih.gov>). The transcription start site was counted as +1 in reference sequences.

Score provided from the RegulomeDB database (<http://regulome.stanford.edu>).

CR, call rate; HWE, Hardy--Weinberg equilibrium; MAF, minor allele frequency.

###### 

Overall and disease‐free survival according to genotypes in patients with non‐small cell lung cancer

                                              Overall survival   Disease‐free survival                                                                    
  ----------- ------------ ------------ ----- ------------------ ----------------------- ------------------- ------- ----------- ---- ------------------- ------
  rs9642391   ivs19+2851   CC           285   96 (33.7)          56                      1.00                        140(49.1)   41   1.00                
                           CG           313   83 (26.5)          63                      0.70 (0.52--0.94)   0.02    145(46.3)   44   0.83 (0.66--1.05)   0.13
                           GG           90    18 (20.0)          67                      0.49 (0.30--0.82)   0.01    35(38.9)    48   0.67 (0.46--0.98)   0.04
                           Dominant                                                      0.65 (0.49--0.86)   0.003                    0.79 (0.63--0.99)   0.04
                           Recessive                                                     0.59 (0.36--0.96)   0.04                     0.74 (0.52--1.06)   0.10
                           Codominant                                                    0.70 (0.56--0.87)   0.001                    0.82 (0.70--0.97)   0.02

Proportion of survival derived from Kaplan--Meier analysis.

Calculated using multivariate Cox proportional hazard models adjusted for age, gender, smoking status, tumor histology, stage, and adjuvant therapy.

5Y‐DFSR, 5‐year disease‐free survival rate; 5Y‐OSR, 5‐year overall survival rate; CI, confidence interval; HR, hazard ratio.

![Kaplan--Meier plot of overall and disease‐free survival curves according to *EGFR* rs9642391C\>G genotype. *P* values, log‐rank test.](TCA-9-916-g002){#tca12757-fig-0001}

The associations of the rs9642391C\>G variant with survival outcomes were further analyzed after classifying the patients by age, gender, smoking status, histological type, and pathologic stage. The rs9642391C\>G genotypes were significantly associated with survival outcomes in men, smokers, and squamous cell carcinoma patients (Table [3](#tca12757-tbl-0003){ref-type="table"}). In adenocarcinoma patients, a correlation was found between the rs9642391C\>G genotypes and survival of smoking adenocarcinoma patients (aHR for OS = 0.67, 95% CI 0.44--1.02; *P* = 0.06). These findings suggested that the rs9642391C\>G variant influences the prognosis of smoking lung cancer patients.

###### 

Stratified analysis of the effects of the rs9642391C\>G genotypes under a codominant model for the minor allele at each polymorphism on survival outcomes by selected variables

                      Overall survival    Disease‐free survival                       
  ------------------- ------------------- ----------------------- ------------------- -------
  Age (years)                                                                         
  \< 64               0.62 (0.43--0.88)   0.01                    0.80 (0.62--1.04)   0.09
  ≥ 64                0.76 (0.58--1.00)   0.05                    0.84 (0.67--1.04)   0.11
  Gender                                                                              
  Male                0.69 (0.54--0.87)   0.002                   0.80 (0.66--0.96)   0.02
  Female              0.83 (0.48--1.45)   0.52                    1.03 (0.72--1.48)   0.86
  Smoking status                                                                      
  Never               0.94 (0.58--1.52)   0.79                    1.12 (0.81--1.54)   0.51
  Ever                0.66 (0.52--0.84)   0.001                   0.75 (0.62--0.91)   0.004
  Histological type                                                                   
  SCC                 0.66 (0.49--0.88)   0.005                   0.74 (0.59--0.94)   0.02
  AC                  0.78 (0.55--1.08)   0.14                    0.90 (0.70--1.15)   0.38
  Smoker AC           0.67 (0.44--1.02)   0.06                    0.69 (0.49--0.96)   0.03
  Never smoker AC     1.16 (0.66--2.04)   0.62                    1.34 (0.94--1.93)   0.11
  Pathologic stage                                                                    
  I                   0.76 (0.51--1.15)   0.20                    0.85 (0.64--1.14)   0.28
  II                  0.57 (0.39--0.82)   0.003                   0.71 (0.52--0.96)   0.02
  IIIA                0.77 (0.53--1.12)   0.17                    0.91 (0.67--1.23)   0.54

Hazard ratios (HRs), 95% confidence intervals (CIs), and corresponding *P* values were calculated using multivariate Cox proportional hazard models, adjusted for other variables.

AC, adenocarcinoma; *P* ~*H*~, *P* value test for homogeneity; SCC, squamous cell carcinoma; SNP, single nucleotide polymorphism.

The rs9642391C\>G variant, which is located in intron 19 of *EGFR*, was predicted to influence the expression of *GBAS* based on RegulomeDB data (<http://regulome.stanford.edu>). Therefore, we evaluated *EGFR* and *GBAS* mRNA levels in 144 tumor and paired non‐malignant lung tissues to confirm these predicted results. The expression levels of *EGFR* and *GBAS* were significantly higher in tumor than in non‐malignant lung tissues (*P* = 2 × 10^−6^ and *P* = 9 × 10^−8^, respectively) (Fig [2](#tca12757-fig-0002){ref-type="fig"}a). *GBAS* expression levels were correlated with *EGFR* expression levels in tumor tissues (*r* = 0.61; *P* = 6.5 × 10^−14^ by Pearson\'s method) (Fig [2](#tca12757-fig-0002){ref-type="fig"}b). *GBAS* expression levels were significantly higher in GG than in CC and CG genotypes (*P* = 0.024, under a recessive model) (Fig [2](#tca12757-fig-0002){ref-type="fig"}c). However, no significant differences in *EGFR* expression levels were observed among patients with different rs9642391C\>G genotypes.

![(**a**) *GBAS* and *EGFR* messenger RNA (mRNA) expression levels in tumor and non‐malignant lung tissues. \**P* \< 0.001 by paired *t*‐test. (**b**) Relationship between *GBAS* and *EGFR* mRNA levels in lung tumor tissue (correlation coefficient = 0.61, *P* \< 0.001 by Pearson\'s method). (**c**) *GBAS* and *EGFR* mRNA expression levels according to rs9642391C\>G genotype in lung tumor tissues.](TCA-9-916-g001){#tca12757-fig-0002}

Discussion {#tca12757-sec-0008}
==========

The first step in identifying the function of non‐coding SNPs is to select the related SNPs that lie within regulatory regions, including enhancer and promoter regions.[14](#tca12757-bib-0014){ref-type="ref"}, [15](#tca12757-bib-0015){ref-type="ref"} In recent years, multiple consortia, such as the ENCODE and the Roadmap Epigenomics Mapping Consortium, have employed a variety of genome‐wide methods to study the chromatin states of non‐coding regions.[16](#tca12757-bib-0016){ref-type="ref"} The RegulomeDB database annotates SNPs with known and predicted regulatory elements of the *Homo sapiens* genome using these public datasets.

In the present study, we investigated the association between potential regulatory SNPs in the *EGFR* gene region and survival of surgically resected early‐stage NSCLC patients. RegulomeDB employs a six‐category system to interpret functional variants.[13](#tca12757-bib-0013){ref-type="ref"} To identify regulatory SNPs, we prioritized SNPs classified under categories 1--3 that were located in the *EGFR* region. Results revealed a significant association between *EGFR* rs9642391C\>G and prognosis of early‐stage NSCLC patients. A previous study indicated that this polymorphism was associated with breast cancer mortality.[17](#tca12757-bib-0017){ref-type="ref"} Consistent with this finding, our results showed that patients harboring the rs9642391 GG or GC genotypes had significantly better OS and DFS compared with those carrying the rs9642391 CC genotype. Our result implies that rs9642391C\>G may play an important role in the pathogenesis of lung cancer.

Although the selected SNPs were located in *EGFR* gene region, RegulomeDB predicted that rs9642391C\>G influences the expression of *GBAS* but not *EGFR*. Our mRNA expression data was consistent with RegulomeDB. *EGFR* rs9642391 resides more than 700kb upstream of the *GBAS* gene, although they are both located in chromosome 7. rs9642391 in intron of *EGFR* belongs to category 1 variants that are known to express quantitative trait loci that have been experimentally shown to be associated with target gene expression. Using the database, we found that rs9642391 lies in a location that overlaps the binding site for DNA binding proteins, such as POLR2A and NFIC, and regulates *GBAS* expression (<http://regulome.stanford.edu/snp/chr7/55245363>). Gene expression is controlled by regulatory elements that can be located further away on the same chromosome or even on other chromosomes.[18](#tca12757-bib-0018){ref-type="ref"} Advances in technologies such as chromosome conformation capture (3C)‐based methods could detect physical interactions between chromosomes, providing convincing evidence for the widespread formation of long range interactions between genes and regulatory elements.[19](#tca12757-bib-0019){ref-type="ref"}, [20](#tca12757-bib-0020){ref-type="ref"} However, further studies are required to establish the functional relevance of these long‐range associations.

A previous study showed that *GBAS* is coamplified with *EGFR* in many cancer cell lines, including lung cancer.[21](#tca12757-bib-0021){ref-type="ref"} In the present study, *EGFR* and *GBAS* mRNA expression consistently showed a significant positive correlation. *GBAS* has an identifiable signal peptide and transmembrane motifs, as well as two tyrosine phosphorylation sites, suggesting that the encoded protein acts as a substrate for tyrosine kinases.[21](#tca12757-bib-0021){ref-type="ref"} Some studies have reported that the GBAS protein is localized to mitochondria and plays a role in oxidative phosphorylation.[22](#tca12757-bib-0022){ref-type="ref"}, [23](#tca12757-bib-0023){ref-type="ref"} However, very little is known about the function of the *GBAS* gene in cancer. According to The Cancer Genome Atlas database and other sources, *GBAS* expression is upregulated compared to normal tissues in many types of cancer, including lung cancer. Although this may suggest that *GBAS* could be a potential oncogene, more direct evidence is needed to confirm its oncogenic function. A study reported that *GBAS* overexpression increases the centrosome amplification rate and facilitates migration and invasion in bladder cancer cell lines, and that high *GBAS* expression correlates with poor survival in bladder cancer patients.[24](#tca12757-bib-0024){ref-type="ref"} However, when survival curves were generated using the Kaplan--Meier Plotter online tool (<http://kmplot.com/analysis/>), which utilizes public databases, higher *GBAS* expression was significantly associated with better survival in lung and gastric cancers and poor survival in breast and ovarian cancers.[25](#tca12757-bib-0025){ref-type="ref"} Therefore, *GBAS* may have tissue and context specific functions in the pathogenesis of various types of cancers. Future studies are warranted to elucidate the role of *GBAS* in lung carcinogenesis and to validate the mechanism of association between the regulatory variant and *GBAS*.

In conclusion, our results show that the rs9642391C\>G variant, which is located in the intron region of *EGFR*, is associated with *GBAS* expression and survival outcomes in surgically resected early‐stage NSCLC patients.
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###### 

**Table S1** Univariate analysis of overall and disease‐free survival by age, gender, smoking status, histological type, pathologic stage, and adjuvant therapy.

###### 

Click here for additional data file.
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